Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vistagen Therapeutics, Inc. - Common Stock
(NQ:
VTGN
)
0.5963
+0.0103 (+1.76%)
Streaming Delayed Price
Updated: 4:00 PM EST, Mar 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vistagen Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Today 13:06 EST
From
Schall Law
Via
GlobeNewswire
VTGN INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline on March 16, 2026
February 26, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
February 26, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference
February 25, 2026
From
Vistagen
Via
Business Wire
Vistagen Therapeutics Inc (NASDAQ:VTGN) Reports Mixed Q3 Results Amid Key Clinical Trial Updates
↗
February 12, 2026
Via
Chartmill
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN
February 24, 2026
From
Pomerantz LLP
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)
February 24, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
February 23, 2026
From
Schall Law
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PomDoctor and Vistagen and Encourages Investors to Contact the Firm
February 21, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN
February 20, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
February 19, 2026
From
Schall Law
Via
GlobeNewswire
VTGN INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline on March 16, 2026
February 19, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
February 19, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN
February 17, 2026
From
Pomerantz LLP
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)
February 17, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
February 16, 2026
From
Schall Law
Via
GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - VTGN
February 14, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
VTGN SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026
February 14, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
VTGN Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Vistagen Therapeutics, Inc. Class Action
February 13, 2026
From
Robbins LLP
Via
GlobeNewswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
February 13, 2026
From
Schall Law
Via
GlobeNewswire
What's going on in today's pre-market session
↗
February 13, 2026
Via
Chartmill
VistaGen (VTGN) Q3 2026 Earnings Call Transcript
↗
February 12, 2026
VistaGen (VTGN) Q3 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Artificial Intelligence
Earnings
Which stocks are moving after the closing bell on Thursday?
↗
February 12, 2026
Via
Chartmill
Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update
February 12, 2026
From
Vistagen
Via
Business Wire
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
February 12, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)
February 10, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
February 10, 2026
From
Schall Law
Via
GlobeNewswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
February 06, 2026
From
Schall Law
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)
February 05, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding The Upcoming Lead Plaintiff Deadline for the Filed Class Action Lawsuit
February 04, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
